Onconic Therapeutics Inc. (KOSDAQ:476060)

Onconic Therapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	58,160	47,046	43,000	30,100	27,316	18,861
Trading Asset Securities	4,456	5,689	-	-	-	-
Cash & Short-Term Investments	62,616	52,735	43,000	30,100	27,316	18,861
Cash Growth	38.57%	22.64%	42.85%	10.19%	44.83%	-
Accounts Receivable	17,387	10,531	7,326	-0	841.52	173.71
Other Receivables	471.03	46.21	254.84	366.74	5.08	2.9
Receivables	17,858	10,578	7,581	366.74	846.6	176.61
Prepaid Expenses	71.94	47.24	-	-	-	-
Other Current Assets	421.42	476.7	1,554	291.85	8.22	10.43
Total Current Assets	80,967	63,837	52,134	30,759	28,171	19,048
Property, Plant & Equipment	3,186	3,060	3,285	3,568	2,619	263.6
Other Intangible Assets	-	0.1	1.27	2.45	3.63	4.8
Long-Term Deferred Tax Assets	8,800	8,800	5,355	3,100	-	-
Other Long-Term Assets	31.59	9.25	137.95	118.38	113.14	110.6
Total Assets	92,984	75,707	60,913	37,548	30,907	19,427

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	4,408	2,669	708.67	-	-	-
Accrued Expenses	91.27	75.51	65.56	82.14	-	-
Current Portion of Leases	186.81	81.27	188.95	154.27	50.72	135.52
Current Income Taxes Payable	-	22.39	463.39	-	-	-
Other Current Liabilities	2,422	774.07	3,339	42,977	26,539	392.14
Total Current Liabilities	7,108	3,623	4,765	43,214	26,590	527.66
Long-Term Leases	84.02	44.53	119.52	199.4	-	53.52
Pension & Post-Retirement Benefits	13.64	-	9.59	3.8	25.04	-
Other Long-Term Liabilities	-	-	0	25.14	26,229	26,823
Total Liabilities	7,206	3,667	4,895	43,442	52,844	27,405

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	22,704	22,245	5,402	2,890	2,890	2,890
Additional Paid-In Capital	26,120	22,576	87,419	7,146	7,146	7,146
Retained Earnings	36,872	26,682	-39,121	-31,019	-32,688	-18,256
Comprehensive Income & Other	82.43	536.94	2,319	1,294	715.69	243.21
Total Common Equity	85,779	72,039	56,019	-19,690	-21,937	-7,978
Shareholders' Equity	85,779	72,039	56,019	-5,894	-21,937	-7,978
Total Liabilities & Equity	92,984	75,707	60,913	37,548	30,907	19,427

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	270.83	125.8	308.47	353.66	50.72	189.04
Net Cash (Debt)	62,345	52,609	42,691	29,747	27,265	18,672
Net Cash Growth	38.64%	23.23%	43.52%	9.10%	46.02%	-
Net Cash Per Share	-	1159.65	1305.39	1286.70	1179.32	815.23
Filing Date Shares Outstanding	-	44.49	43.22	36.83	23.12	22.9
Total Common Shares Outstanding	-	44.49	43.22	36.83	23.12	22.9
Working Capital	73,859	60,214	47,369	-12,454	1,581	18,520
Book Value Per Share	-	1619.23	1296.26	-534.61	-948.83	-348.30
Tangible Book Value	85,779	72,039	56,018	-19,692	-21,941	-7,982
Tangible Book Value Per Share	-	1619.23	1296.23	-534.68	-948.99	-348.51
Land	570.58	570.58	570.58	570.58	-	-
Buildings	1,617	1,617	1,617	1,617	-	-
Machinery	1,667	1,495	1,138	1,033	-	-

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 1, 2026

Data Sources Report a data error